Fate Therapeutics Amasses More Academic Stem Cell IP with Children's Hospital Boston Deal

The exclusive license also covers technology developed by a Massachusetts General Hospital researcher, and brings to seven the number of universities or research institutions with which Fate has licensed IP for using small molecules and biologics to modulate stem cells for therapeutic purposes.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.